Applications of Sulindac Sulfide in Industrial Manufacturing

Sulindac Sulfide serves critical roles across several specialized sectors due to its chemical structure, pharmacological properties, and compatibility with stringent regulatory frameworks. As the original manufacturer, we supply this material for advanced industrial and scientific purposes where quality, consistency, and process transparency are fundamental.

1. Pharmaceutical Active Ingredient Production

Sulindac Sulfide is widely utilized as the principal active pharmaceutical ingredient (API) in the manufacturing of non-steroidal anti-inflammatory drugs (NSAIDs). API production demands full traceability, material purity, and compliance with mono- and multi-compendial pharmacopeial requirements. Formulators integrate Sulindac Sulfide during the granulation or direct compression phases, adjusting concentrations based on clinical dosage forms intended for regulatory approval. Production plants must maintain validated cleaning, segregation, and controlled atmosphere systems to prevent cross-contamination with other APIs.

Industry compliance standards

• USP (United States Pharmacopeia)
• EP (European Pharmacopeia)
• JP (Japanese Pharmacopeia)
• CGMP (21 CFR Parts 210/211)
• ICH Q7 API manufacturing guidelines

Typical usage ratio

• 10%–35% of tablet or capsule mass, adjusted to meet dosage strengths ranging from 100 mg to 400 mg per unit as per product labeling and regulatory submission.

Downstream process integration

• Incorporated during the pharmaceutical blending, granulation, or tablet compression stage, after initial milling and sieving to precise particle size distribution.

Final product types

• Oral tablets
• Capsules
• Prescription NSAID formulations

2. Pharmaceutical Intermediate Synthesis

Chemical manufacturers adopt Sulindac Sulfide as an advanced synthetic intermediate for the production of analogues and derivatives used in further pharmaceutical research, generic development, and custom synthesis contracts. Strict control of impurity profiles and process validation documentation is essential for compliance prior to transfer into downstream secondary manufacturing stages. Sulindac Sulfide enters at designated mid-stage reactor steps where its reactivity and compatibility enable targeted structural modifications necessary for proprietary or generic pharmaceutical products.

Industry compliance standards

• ISO 9001:2015 for quality management systems
• REACH registration (EC 1907/2006) for European chemical operations
• ICH Q11 for development and manufacture of drug substances

Typical usage ratio

• Varies from 5%–50% molar stoichiometry in multi-step syntheses, custom adjusted for targeted intermediate yields.

Downstream process integration

• Charged into reactors during second or third synthesis stage; monitored for complete conversion and downstream acid, base, or catalytic transformations to fabricate high-purity pharmaceutical intermediates.

Final product types

• API intermediates
• Novel chemical entities for clinical trials
• Process validation lots for generic drugs

3. Analytical Reference Material Supply

Analytical laboratories and pharma QC units purchase Sulindac Sulfide as a certified reference material (CRM) for method development, validation, impurity profiling, and pharmacokinetic quantitation in post-manufacture release testing. Stringent batch homogeneity, validated purity, and comprehensive documentation (certificates of analysis, traceability to NIST or equivalent) ensure suitability for pharmacopeial identification and potency assays. Laboratories require supply in small, precisely characterized lots for accuracy in HPLC, GC, and LC-MS system calibration.

Industry compliance standards

• ISO/IEC 17025 for analytical laboratory competence
• ISO 17034 for reference material producers
• USP/EP/JP pharmacopoeial method verification guidelines

Typical usage ratio

• Applied as 0.1–1% w/w calibration standards in chromatographic and spectrometric analysis, subject to lab SOPs and relevant method validation ranges.

Downstream process integration

• Diluted and dispensed during instrument calibration and analytical batch QC, serving as assay standard or system suitability control prior to, during, and after API manufacturing runs.

Final product types

• Pharmacopoeial reference standards
• Analytical calibration kits
• Pre-filled QC vials for process validation

4. Preclinical Toxicology Research

Preclinical CROs (Contract Research Organizations) and toxicology labs utilize Sulindac Sulfide in controlled study designs to investigate absorption, distribution, metabolism, excretion (ADME), and safety profile in proprietary animal models. Full batch analytical data traceable to pharmaceutical GMP or GLP standards is mandatory. Compound integration requires solubility characterization, vehicle compatibility determination, and accurate dosing regimens to align with documented toxicological endpoints set by regulatory authorities.

Industry compliance standards

• GLP (Good Laboratory Practice) as per OECD and US FDA 21 CFR Part 58
• AAALAC International guidelines for animal studies
• REACH and local chemical safety rules for laboratory environments

Typical usage ratio

• Dosing ranges from 0.5 mg/kg to 100 mg/kg body weight in test animals, set by study protocol, route of administration, and expected toxicology endpoint.

Downstream process integration

• Dispensed into formulation vehicles during study preparation phase; administered to animal cohorts via oral gavage, injection, or feed admixture as stipulated in the study plan.

Final product types

• Preclinical toxicology study reports
• Regulatory submission dossiers (IND, CTA)
• Pharmacokinetic and safety data packages

5. Solid-State Pharmaceutical Characterization

R&D and process development labs in pharmaceutical technology employ Sulindac Sulfide for crystal polymorphism studies and solid-state form screening. Material supplied in microcrystalline, amorphous, or specified particle sizes enables systematic investigation of solubility, stability, and compressibility effects in direct formulation design. Characterization data contributes to drug product quality by supporting formulation selection, risk mitigation, and ICH-driven regulatory filings.

Industry compliance standards

• ICH Q6A Specifications: Test Procedures and Acceptance Criteria
• USP <941> Characterization of Crystalline and Amorphous Solids
• EP General Methods 2.9.35 for powder flow

Typical usage ratio

• Evaluated in 5 mg to 50 g batches per study; sizing and composition depend on analytical protocol and stage of solid-state investigation.

Downstream process integration

• Weighing and dispersing into series of solid-state, thermal, and dissolution test matrices prior to prototype dosage form preparation.

Final product types

• Crystallization process development reports
• Polymorph screening data sets
• Regulatory submission documentation for NDA/ANDA filings